GleamWall
中文EN

NBP NovaBridge Biosciences

Pharmaceutical Preparations · Nasdaq · SEC CIK 1778016 · Fiscal year ends 12/31

Financial factors as of 2023-12-31 (FY2023), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY140.7%
TTM net income YoY44.0%
TTM EPS YoY44.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-11,395.1%
Net margin-32,868.5%
FCF margin-11,528.6%
EBITDA margin-11,319.9%

Returns

ROE-62.9%
ROA-43.3%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets34.2%
Debt / equity0.00x
Current ratio5.67x
Interest coverage-706.05x

Cash quality & payout

Operating cash flow / net income0.35x
Accruals ratio-28.1%
Payout ratio—
Capex / revenue25.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$62.91M$21.77M
SG&A expense$31.36M$29.66M
Operating income-$94.27M-$51.43M
Pretax income-$88.34M-$49.70M
Income tax$0$0
Net income-$46.27M-$22.23M
EBITDA-$94.20M-$51.16M
EPS (basic)-0.21-0.12
EPS (diluted)-0.21-0.12
Weighted avg. shares (diluted)220.26M186.73M
Balance sheet
Cash & equivalents$210.63M$68.26M
Short-term investments$210,000$105.14M
Current assets$217.52M$176.69M
PP&E, net$140,000$201,000
Total assets$260.52M$212.68M
Current liabilities$26.89M$8.45M
Total liabilities$29.58M$11.52M
Shareholders' equity$230.94M$201.16M
Shares outstanding265.38M187.45M
Cash flow statement
Operating cash flow-$20.60M-$52.67M
Capital expenditure$7,000$48,000
Free cash flow-$20.60M-$52.72M
Investing cash flow$104.97M-$136.01M
Financing cash flow$57.73M-$335,000
Depreciation & amortization$68,000$261,000
Stock-based compensation$5.97M-$1.95M

Free plan shows the latest 2 periods; Pro shows all 10 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.